Regulatory approval proves a drug is safe and effective against a placebo or comparator in a trial population. Payer reimbursement asks whether it is worth more than what they already cover, at a cost the budget can bear. Market access teams have to build that separate case, using real-world value and comparator evidence, well before launch.
Why doesn't a trial result settle the reimbursement question?
A pivotal trial is built to satisfy a regulator, and a regulator's question is narrow: does this molecule do what it claims, more safely and more effectively than a placebo or an active comparator, in a defined population, over a defined period. Every design choice in the trial serves that one question.
A payer's question is different and comes later. It is not whether the drug works, it is whether the drug works well enough to displace something already being paid for, at a price the system can sustain across the full population that will actually use it, not the narrower one enrolled in the study. Progression-free survival or a biomarker shift satisfies the regulator; it does not tell a payer what happens to total spend, hospitalisation rates, or productivity once the drug leaves the trial and meets a messier patient population.
- 01
Scope evidence needs early
Map comparator, endpoint, and subgroup requirements market by market, starting around Phase II.
- 02
Commission comparative and real-world evidence
Fill the gap between trial endpoints and payer-relevant outcomes before the dossier is locked.
- 03
Engage payers and physicians pre-launch
Test the value story with formulary reviewers and treating physicians ahead of submission.
- 04
Align pricing to the access strategy
Set price and contracting terms alongside the evidence plan, not after a rejection.
What does a payer actually need proved?
Three things, roughly, and none of them come free from the registration trial. Comparative effectiveness against the therapies actually in use in that market, not just the comparator arm the trial happened to choose, since the standard of care in a submission dossier often differs by geography. Budget impact, meaning what the drug costs the system net of what it displaces, modelled across realistic uptake curves rather than an optimistic launch scenario.
And real-world value: outcomes that matter to a payer's budget and a patient's life outside a controlled trial setting, adherence, reduced hospitalisation, caregiver burden, the things a twelve-week endpoint was never built to capture. A submission that leans only on the trial's primary endpoint tends to stall at exactly this point, because the reviewer's job is to ask what the endpoint means for the population they actually fund.
Why does the case need to start before launch?
Because most of the gaps above cannot be closed retroactively. Comparator data, real-world evidence infrastructure, and health economic models all take longer to build than a launch timeline allows if the work only starts after approval. A market access team that begins scoping payer evidence needs during Phase II, rather than after Phase III reads out, has time to commission the comparative studies and build the economic model the actual target markets will ask for.
This is also where structured payer and physician research earns its place well ahead of a filing. Talking to payer committees, formulary reviewers, and treating physicians before the dossier is locked reveals which comparators and outcomes actually matter in a given market, rather than guessing from the trial design alone. A pricing and access strategy set after launch is usually a strategy built around the evidence the company happens to have, not the evidence the market asked for.
| US payer system | Single-payer / HTA market | |
|---|---|---|
| Decision structure | Fragmented, plan by plan | Centralised, one national verdict |
| Evidence bar | Variable, negotiated per payer | Explicit cost-effectiveness threshold |
| Consequence of a weak dossier | Restricted tier on some plans | Access denied across the population |
How does the US payer system differ from single-payer and HTA markets?
In the US, market access runs through a fragmented set of private and public payers, each running its own formulary and utilisation management decisions, with no single national verdict on value. A drug can be reimbursed generously by one plan and restricted by another, and the negotiating leverage sits substantially with pharmacy benefit managers rather than a single clinical body.
In single-payer and HTA-body markets, the decision is centralised and the bar is more explicit. Bodies conducting health technology assessment weigh cost-effectiveness against a defined threshold, usually expressed as cost per quality-adjusted life year, and one national decision effectively sets access for the whole population. The evidence dossier for an HTA body is more standardised and more numerically explicit than a US payer submission, but there is no second chance at a different plan once that verdict lands.
What does a market access team actually do day to day?
Translate clinical and commercial evidence into the specific formats each payer or HTA body requires, which is less a writing exercise than a research one. It means identifying which comparators, endpoints, and subgroups a given market will scrutinise, then making sure the evidence generation plan produces that data before the submission window, not after a rejection.
It also means pricing strategy work, since price and access are the same negotiation in most systems, and stakeholder engagement with payers, physicians, and patient groups long before the label is final. The team that treats market access as a post-approval filing function is, in most cases, the team explaining a rejected submission a year later rather than the one that avoided it.